The BRAF V600E mutation in papillary thyroid cancer with positive or suspected pre-surgical cytological finding is not associated with advanced stages or worse prognosis

Abstract

The mutation BRAF V600E is thought to be a putative prognostic marker of the aggressiveness of several cancers among which is also papillary thyroid cancer. Our study aimed to evaluate whether this mutation is associated with advanced stages of disease or with a worse prognosis in a series of patients with cytological findings of Thyr 4 and Thyr 5 and who were undergoing total thyroidectomy and routine central compartment lymph-node dissection. 110 patients were consecutively enrolled over an 18-month period from September 2010 to March 2012. All patients had cytological findings that were either indicative of, or positive for papillary thyroid cancer, Thyr 4 or Thyr 5. Detection of BRAF mutation was made on fine-needle aspiration specimen by pyrosequencing after microdissection and DNA extraction of neoplastic cells. After surgical intervention, the patients underwent radioiodine ablation according to our protocol, and follow-up was performed after 8 months. The BRAF V600E mutation was found in 79 % of our cases: 85.7 % of these cases represented the classical variant, 57.8 % the follicular variant, 89.6 % the tall cell variant, and 33.3 % the solid variant. All patients had confirmation of papillary thyroid cancer after histology, with no differences being seen in pTNM presentation between patients with BRAF wild-type and patients with BRAF V600E mutation. Ninety-nine patients underwent radioiodine ablation. Results at follow-up 8 months after radioiodine ablation showed no differences in the rate of ablation between patients harboring BRAF V600E mutation and those having BRAF wild-type. The BRAF V600E mutation doesn’t appear to be a reliable risk factor for the aggressiveness of a tumor. BRAF analysis should neither be the only guide for pre-surgical decisions regarding the extent of surgery nor for post-surgical decisions regarding the aggressiveness of the treatment.

This is a preview of subscription content, log in to check access.

Fig. 1
Fig. 2

References

  1. 1.

    R. Siegler, D. Naishadham, A. Jemal, Cancer statistics 2012. CA Cancer J. Clin. 62(1), 10–29 (2012)

    Article  Google Scholar 

  2. 2.

    M.J. Schlumberger, Papillary and follicular thyroid carcinoma. N. Engl. J. Med. 338(5), 297–306 (1998)

    CAS  PubMed  Article  Google Scholar 

  3. 3.

    V. Popovici, E. Budinska, S. Teipar, S. Weinrich, H. Estrella, G. Hodgson, E. Van Cutsem, T. Xie, F.T. Bosman, A.D. Roth, M. Delorenzi, Identification of a poor-prognosis BRAF-mutant-like population of patients with colon cancer. J. Clin. Oncol. 30(12), 1288–1295 (2012)

    CAS  PubMed  Article  Google Scholar 

  4. 4.

    J. Ziai, P. Hui, BRAF mutation testig in clinical practice. Expert Rev. Mol. Diagn. 12(2), 127–138 (2012)

    CAS  PubMed  Article  Google Scholar 

  5. 5.

    M.A. Zeiger, E.B. Schneider, BRAF V600E mutation independently predicts central compartment lymph node metastasis in patients with papillary thyroid cancer. Ann. Surg. Oncol. 20(1), 3–4 (2013)

    PubMed  Article  Google Scholar 

  6. 6.

    R.P. Tufano, J. Bishop, G. Wu, Reoperative central compartment dissection for patients with recurrent/persistent papillary thyroid cancer: efficacy, safety, and the association of the BRAF mutation. Laryngoscope 122(7), 1634–1640 (2012)

    CAS  PubMed  Article  Google Scholar 

  7. 7.

    G.M. Howell, S.E. Carty, M.J. Armstrong, S.O. Lebeau, S.P. Hodak, C. Coyne, M.T. Stang, K.L. McCoy, M.N. Nikiforova, Y.E. Nikiforov, L. Yip, Both BRAF V600E mutation and older age (≥65 years) are associated with recurrent papillary thyroid cancer. Ann. Surg. Oncol. 18(13), 3566–3571 (2011)

    PubMed  Article  Google Scholar 

  8. 8.

    G.M. Howell, M.N. Nikiforova, S.E. Carty, M.J. Armstrong, S.P. Hodak, M.T. Stang, K.L. McCoy, Y.E. Nikiforov, L. Yip, BRAF V600E mutation independently predicts central compartment lymph node metastasis in patients with papillary thyroid cancer. Ann. Surg. Oncol. 20(1), 47–52 (2012)

    PubMed  Article  Google Scholar 

  9. 9.

    S.J. Kim, K.E. Lee, J.P. Myong, J.H. Park, Y.K. Jeon, H.S. Min, S.Y. Park, K.C. Jung, H. Koo do, Y.K. Youn, BRAF V600E mutation is associated with tumor aggressiveness in papillary thyroid cancer. World J. Surg. 36(2), 310–317 (2012)

    PubMed  Article  Google Scholar 

  10. 10.

    W. Wang, W. Zhao, H. Wang, X. Teng, H. Wang, X. Chen, Z. Li, X. Yu, T.J. Fahey 3rd, L. Teng, Poorer prognosis and higher prevalence of BRAF (V600E) mutation in synchronous bilateral papillary thyroid carcinoma. Ann. Surg. Oncol. 19(1), 31–36 (2012)

    PubMed  Article  Google Scholar 

  11. 11.

    A. Chakraborty, A. Narkar, R. Mukhopadhyaya, S. Kane, A. D’Cruz, M.G. Rajan, BRAF V600E mutation in papillary thyroid carcinoma: significant association with node metastases and extra thyroidal invasion. Endocr. Pathol. 23(2), 83–93 (2012)

    CAS  PubMed  Article  Google Scholar 

  12. 12.

    N. Kurtulmus, M. Duren, U. Ince, M. Cengiz Yakicier, O. Peker, O. Aydın, E. Altiok, S. Giray, H. Azizlerli, BRAF(V600E) mutation in Turkish patients with papillary thyroid cancer: strong correlation with indicators of tumor aggressiveness. Endocrine 42(2), 404–410 (2012)

    CAS  PubMed  Article  Google Scholar 

  13. 13.

    Y.L. Zhou, W. Zhang, E.L. Gao, X.X. Dai, H. Yang, X.H. Zhang, O.C. Wang, Preoperative BRAF mutation is predictive of occult contralateral carcinoma in patients with unilateral papillary thyroid microcarcinoma. Asian Pac. J. Cancer Prev. 13(4), 1267–1272 (2012)

    PubMed  Article  Google Scholar 

  14. 14.

    X. Lee, M. Gao, Y. Ji, Y. Yu, Y. Feng, Y. Li, Y. Zhang, W. Cheng, W. Zhao, Analysis of differential BRAF V600E mutational status in high aggressive papillary thyroid microcarcinoma. Ann. Surg. Oncol. 16(2), 240–245 (2009)

    PubMed  Article  Google Scholar 

  15. 15.

    R. Elisei, D. Viola, L. Torregrossa, R. Giannini, C. Romei, C. Ugolini, E. Molinaro, L. Agate, A. Biagini, C. Lupi, L. Valerio, G. Materazzi, P. Miccoli, P. Piaggi, A. Pinchera, P. Vitti, F. Basolo, The BRAF V600 E mutation is an indipendent, poor prognostic factor fort the out come of patients with low-risk intrathyroid papillary thyroid carcinoma: single-institution results from a large cohort study. J. Clin. Endocrin. Metab. 97(12), 4390–4398 (2012)

    CAS  Article  Google Scholar 

  16. 16.

    J.Y. Joo, J.Y. Park, Y.H. Yoon, B. Choi, J.M. Kim, Y.S. Jo, M. Shong, B.S. Koo, Prediction of occult central lymph node metastasis in papillary thyroid carcinoma by preoperative BRAF analysis using fine-needle aspiration biopsy: a prospective study. J. Clin. Endocrinol. Metab. 97(11), 3996–4003 (2012)

    CAS  PubMed  Article  Google Scholar 

  17. 17.

    C. Nucera, A. Pontecorvi, Clinical outcome, role of BRAF(V600E), and molecular pathways in papillary thyroid microcarcinoma: is it an indolent cancer or an early stage of papillary thyroid cancer? Front Endocrinol. (Lausanne) 3, 33 (2012)

    CAS  Google Scholar 

  18. 18.

    R.P. Tufano, G.V. Teixeira, J. Bishop, K.A. Carson, M. Xing, BRAF mutation in papillary thyroid cancer and its value in tailoring initial treatment: a systematic review and meta-analysis. Medicine (Baltimore) 91(5), 274–286 (2012)

    CAS  Article  Google Scholar 

  19. 19.

    C. Nucera, J. Lawler, R. Hodin, S. Parangi, The BRAF V600E mutation: what is really orchestrating in thyroid cancer? Oncotarget 1(8), 751–756 (2010)

    PubMed Central  PubMed  Google Scholar 

  20. 20.

    Dutenhefner SE, Marui S, Santos AB, Lima EU, Inoue M, Neto JD, Shiang C, Fukushima J, Cernea CR, Friguglietti C 2012 BRAF, a tool in the decision to perform elective neck dissection? Thyroid Nov 27 (2012)

  21. 21.

    X. Li, A.B. Abdel-Mageed, E. Kandil, BRAF mutation in papillary thyroid carcinoma. Int. J. Clin. Exp. Med. 5(4), 310–315 (2012)

    CAS  PubMed Central  PubMed  Google Scholar 

  22. 22.

    H. Pelttari, C. Schalin-Jäntti, J. Arola, E. Löyttyniemi, S. Knuutila, M.J. Välimäki, BRAF V600E mutation does not predict recurrence after long-term follow-up in TNM stage I or II papillary thyroid carcinoma patients. APMIS 120(5), 380–386 (2012)

    CAS  PubMed  Article  Google Scholar 

  23. 23.

    C. Eloy, J. Santos, P. Soares, M. Sobrinho-Simoes, The preeminence of growth pattern and invasiveness and the limited influence of BRAF and RAS mutations in the occurrence of papillary thyroid carcinoma lymph node metastases. Virchows Arch. 459(3), 265–276 (2011)

    CAS  PubMed  Article  Google Scholar 

  24. 24.

    J.K. Nam, C.K. Jung, B.J. Song, D.J. Lim, B.J. Chae, N.S. Lee, W.C. Park, J.S. Kim, S.S. Jung, J.S. Bae, Is the BRAF (V600E) mutation useful as a predictor of preoperative risk in papillary thyroid cancer? Am. J. Surg. 203(4), 436–441 (2012)

    CAS  PubMed  Article  Google Scholar 

  25. 25.

    D. Ahn, J.S. Park, J.H. Sohn, J.H. Kim, S.K. Park, A.N. Seo, J.Y. Park, BRAF (V600E) mutation does not serve as a prognostic factor in Korean patients with papillary thyroid carcinoma. Auris Nasus Larynx 39(2), 198–203 (2012)

    PubMed  Article  Google Scholar 

  26. 26.

    T.Y. Kim, W.B. Kim, J.Y. Song, Y.S. Rhee, G. Gong, Y.M. Cho, S.Y. Kim, S.C. Kim, S.J. Hong, Y.K. Shong, The BRAF mutation is not associated with poor prognostic factors in Korean patients with conventional papillary thyroid microcarcinoma. Clin. Endocrinol. (Oxf) 63(5), 588–593 (2005)

    CAS  Article  Google Scholar 

  27. 27.

    T.H. Kim, Y.J. Park, J.A. Lim, H.Y. Ahn, E.K. Lee, Y.J. Lee, K.W. Kim, S.K. Hahn, Y.K. Youn, K.H. Kim, B.Y. Cho, J. do Park, The association of the BRAF(V600E) mutation with prognostic factors and poor clinical outcome in papillary thyroid cancer: a meta-analysis. Cancer 118(7), 1764–1773 (2012)

    CAS  PubMed  Article  Google Scholar 

  28. 28.

    C. Li, K.C. Lee, B. Schneider, M.A. Zeiger, BRAF V600E mutation and its association with clinicopathological features of papillary thyroid cancer: a meta-analysis. J. Clin. Endocrinol. Metab. 97(12), 4559–4570 (2012)

    CAS  PubMed Central  PubMed  Article  Google Scholar 

  29. 29.

    K.C. Lee, C. Li, E.B. Schneider, Y. Wang, H. Somervell, M. Krafft, C.B. Umbricht, M.A. Zeiger, Is BRAF Imutation associated with lymph node metastasis in patients with papillary thyroid cancer? Surgery 152(6), 977–983 (2012)

    PubMed Central  PubMed  Article  Google Scholar 

  30. 30.

    Y.K. So, Y.I. Son, J.Y. Park, C.H. Baek, H.S. Jeong, M.K. Chung, Preoperative BRAF Mutation has different predictive values for lymph node metastasis according to tumor size. Otolaryngol. Head Neck Surg. 145(3), 422–427 (2011)

    PubMed  Article  Google Scholar 

  31. 31.

    A. Proietti, R. Giannini, C. Ugolini, M. Miccoli, G. Fontanini, G. Di Coscio, R. Romani, P. Berti, P. Miccoli, F. Basolo, BRAF status of follicular variant of papillary thyroid carcinoma and its relationship to its clinical and cytological features. Thyroid 20(11), 1263–1270 (2010)

    PubMed  Article  Google Scholar 

  32. 32.

    C. Romei, L. Fugazzola, E. Puxeddu, F. Frasca, D. Viola, M. Muzza, S. Moretti, L.M. Nicolosi, C. Giani, V. Cirello, N. Avenia, S. Rossi, P. Vitti, A. Pinchera, R. Elisei, Modifications in the papillary thyroid cancer gene profile over the last 15 years. J. Clin. Endocrinol. Metab. 97(9), E1758–E1765 (2012)

    CAS  PubMed  Article  Google Scholar 

  33. 33.

    J.D. Prescott, P.M. Sadow, R.A. Hodin, L.P. Le, R.D. Gaz, G.W. Randolph, A.E. Stephen, S. Parangi, G.H. Daniels, C.C. Lubitz, BRAF (V600E) status adds incremental value to current risk classification systems in predicting papillary thyroid carcinoma recurrence. Surgery 152(6), 984–990 (2012)

    PubMed Central  PubMed  Article  Google Scholar 

  34. 34.

    D.S. Cooper, G.M. Doherty, B.R. Haugen, R.T. Kloos, S.L. Lee, S.J. Mandel, E.L. Mazzaferri, B. McIver, F. Pacini, M. Schlumberger, S.I. Sherman, D.L. Steward, R.M. Tuttle, American Thyroid Association (ATA) guidelines taskforce on thyroid nodules and differentiated thyroid cancer. Thyroid 19(11), 1167–1214 (2009)

    PubMed  Article  Google Scholar 

  35. 35.

    M. Xing, A.S. Alzahrani, K.A. Carson, D. Viola, R. Elisei, B. Bendlova, L. Yip, C. Mian, F. Vianello, R.M. Tuttle, E. Robenshtok, J.A. Fagin, E. Puxeddu, L. Fugazzola, A. Czarniecka, B. Jarzab, C.J. O’Neill, Sywak, A.K. Lam, G. Riesco-Eizaguirre, P. Santisteban, H. Nakayama, R.P. Tufano, S.I. Pai, M.A. Zeiger, W.H. Westra, D.P. Clark, R. Clifton-Bligh, D. Sidransky, P.W. Ladenson, V. Sykorova, Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer. JAMA 309(14), 1493–1501 (2013)

    CAS  PubMed Central  PubMed  Article  Google Scholar 

  36. 36.

    J.C. Watkinson, The Brithish Thyroid Association guidelines for the management of thyroid cancer in adults. Nucl. Med. Commun. 25(9), 897–900 (2004)

    PubMed  Article  Google Scholar 

  37. 37.

    A. Guerra, V. Marotta, M. Deandrea, M. Motta, P.P. Limone, A. Caleo, P. Zeppa, S. Esposito, F. Fulciniti, M. Vitale, BRAF (V600E) associates with cytoplasmatic localization of p27kip1 and higher cytokeratin 19 expression in papillary thyroid carcinoma. Endocrine (2012). doi:10.1007/s12020-012-9843-4

    PubMed  Google Scholar 

  38. 38.

    C. Durante, E. Puxeddu, E. Ferretti, R. Morisi, S. Moretti, R. Bruno, F. Barbi, N. Avenia, A. Scipioni, A. Verrienti, E. Tosi, A. Cavaliere, A. Gulino, S. Filetti, D. Russo, BRAF mutations in papillary thyroid carcinomas inhibit genes involved in iodine metabolism. J. Clin. Endocrinol. Metab. 92(7), 2840–2843 (2007)

    CAS  PubMed  Article  Google Scholar 

  39. 39.

    Pupilli C, Pinzani P, Salvianti F, Fibbi B, Rossi M, Petrone L, Perigli G, De Feo M, Vezzosi V, Pazzagli M, Orlando C, Forti G Circulating BRAFV600E in the diagnosis and follow up of differentiated papillary thyroid carcinoma. J. Clin. Endocrinol. Metab. Jun 20 (2013)

  40. 40.

    Lim JY, Hong SW, Lee YS, Kim BW, Park CS, Chang HS, Cho JY Clinicopathologic implications of the BRAFV600E mutation in papillary thyroid cancer; a subgroup analysis of 3130 cases in a single center. Thyroid Mar 17 (2013)

  41. 41.

    E. Puxeddu, C. Durante, N. Avenia, S. Filetti, D. Russo, Clinical implications of BRAF muttion in thyroid carcinoma. Trends Endocrinol. Metab. 19(4), 138–145 (2008)

    CAS  PubMed  Article  Google Scholar 

  42. 42.

    M. Xing, Prognostic utility of BRAF mutation in papillary thyroid cancer. Mol. Cell. Endocrinol. 32(1), 86–93 (2010)

    Article  Google Scholar 

  43. 43.

    Wartofsky L Should patients with papillary microcarcinoma undergo radioiodine ablation? Endocrine Jul 2 (2013)

  44. 44.

    Kunavisarut T Diagnostic biomarkers of differentiated thyroid cancer. Endocrine May 4 (2013)

  45. 45.

    Guerra A, Di Stasi V, Zeppa P, Faggiano A, Marotta V, Vitale M BRAF V600E assessment by pyrosequencing in fine needle aspirates of thyroid nodules with concurrent Hashimoto’s thyroiditis is a reliable assay. Endocrine Dec 1 (2013)

Download references

Conflict of interest

Nothing to declare.

Author information

Affiliations

Authors

Corresponding author

Correspondence to Daniele Barbaro.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Barbaro, D., Incensati, R.M., Materazzi, G. et al. The BRAF V600E mutation in papillary thyroid cancer with positive or suspected pre-surgical cytological finding is not associated with advanced stages or worse prognosis. Endocrine 45, 462–468 (2014). https://doi.org/10.1007/s12020-013-0029-5

Download citation

Keywords

  • BRAF V600E mutation
  • Papillary thyroid cancer
  • Thyr 4
  • Thyr 5